Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piperacillin/Tazobactam Prolonged vs. Intermittent Infusion for Nosocomial Pneumonia
NCT01796717Phase 3Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2012
- Primary completion
- Nov 2016
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of piperacillin + tazobactam in hospital-acquired pneumonia (HAP), Bacteremia, sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
piperacillin + tazobactam
03
Conditions
hospital-acquired pneumonia (HAP)Bacteremia
Beyond the preview
Go deeper on NCT01796717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01796717.